Charles J. Ryan

Abiraterone and Increased Survival in Metastatic Prostate Cancer

Johann S. de Bono, Christopher J. Logothetis, Arturo Molina et al. · New England Journal of Medicine · 2011 · 4.3K citations · Full text

Abiraterone in Metastatic Prostate Cancer without Previous Chemotherapy

Charles J. Ryan, Matthew R. Smith, Johann S. de Bono et al. · New England Journal of Medicine · 2012 · 2.8K citations · Full text

Trial Design and Objectives for Castration-Resistant Prostate Cancer: Updated Recommendations From the Prostate Cancer Clinical Trials Working Group 3

Howard I. Scher, Michael J. Morris, Walter M. Stadler et al. · Journal of Clinical Oncology · 2016 · 1.5K citations · Full text

Abiraterone acetate plus prednisone versus placebo plus prednisone in chemotherapy-naive men with metastatic castration-resistant prostate cancer (COU-AA-302): final overall survival analysis of a randomised, double-blind, placebo-controlled phase 3 study

Charles J. Ryan, Matthew R. Smith, Karim Fizazi et al. · The Lancet Oncology · 2015 · 1.3K citations

Urology, Oncology, Prednisone Versus Placebo +7

Clinical and Genomic Characterization of Treatment-Emergent Small-Cell Neuroendocrine Prostate Cancer: A Multi-institutional Prospective Study

Rahul Aggarwal, Jiaoti Huang, Joshi J. Alumkal et al. · Journal of Clinical Oncology · 2018 · 776 citations · Full text

T-scnc Detection, Urology, Genitourinary Cancer +11